Log In
Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Forgot your password?
Log In
Don't have an account? Sign Up Here
Join Us
Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
I agree to TheMaven's
Terms
and
Policy
Sign Up
Already have an account? Login here
JIM CRAMER
INVESTING
PERSONAL FINANCE
RETIREMENT
TECHNOLOGY
MARKETS
HOW-TO
VIDEO
FINANCIAL ADVISOR CENTER
Search
Trade with Jim Cramer 14 Days Free
Join the Action Alerts PLUS Community today!
SUBSCRIBE NOW
LATEST NEWS
INVESTING
Audentes Therapeutics Soars on Astellas Pharma's $3 Billion Purchase
By Rob Lenihan
Dec 3, 2019 11:09 AM EST
PRESS RELEASES
Astellas Submits Supplemental New Drug Application For Approval Of Evrenzo® (roxadustat) For The Treatment Of Anemia Associated With Chronic Kidney Disease In Non-Dialysis Dependent Patients In Japan
By PR Newswire
Jan 30, 2020 12:01 AM EST
PRESS RELEASES
Astellas Completes Acquisition Of Audentes Therapeutics
By PR Newswire
Jan 15, 2020 8:22 AM EST
PRESS RELEASES
Astellas Strengthens Immuno-oncology Pipeline With Acquisition Of Xyphos Biosciences, Inc.
By PR Newswire
Dec 26, 2019 7:30 PM EST
INVESTING
Audentes Therapeutics Soars on Astellas Pharma's $3 Billion Purchase
By Rob Lenihan
Dec 3, 2019 11:09 AM EST
INVESTING
Sanofi threatens to go hostile in Medivation battle
By Sarah Pringle
May 5, 2016 11:26 AM EDT
OPINION
Will a third Medivation suitor present itself?
By Alicia McElhaney
May 4, 2016 1:08 PM EDT
OPINION
Sanofi first quarter shows why it wants but doesn't need Medivation
By Paul Whitfield
Apr 29, 2016 10:50 AM EDT
MERGERS AND ACQUISITIONS
Sanofi Presses Medivation to Hold Talks After $9.3B Offer
By Adam Feuerstein
Apr 28, 2016 7:00 AM EDT
INVESTING
Medivation jumps after reportedly hiring bankers to fight takeover
By The Fly Staff
Mar 31, 2016 9:47 AM EDT
